A phase 3, open-label, randomized study of the FLT3 inhibitor gilteritinib versus salvage chemotherapy in adults with first relapse or primary refractory FLT3 mutation-positive acute myeloid leukemia.

被引：3

作者：

Perl, Alexander E.

Cortes, Jorge E.

Strickland, Stephen Anthony

Ritchie, Ellen K.

Neubauer, Andreas

Martinelli, Giovanni

Naoe, Tomoki

Pigneux, Arnaud

Rousselot, Philippe H.

Rollig, Christoph

Baer, Maria R.

Larson, Richard A.

James, Angela Joubert

Chen, Caroline

Shu, Lei

Hasabou, Nahla

Bahceci, Erkut

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[4] Cornell Univ, Weill Cornell Med Coll, New York, NY 10021 USA

[5] Univ Clin Giessen Marburg, Marburg, Germany

[6] Univ Bologna, Bologna, Italy

[7] Natl Hosp Org, Nagoya, Aichi, Japan

[8] CHU Bordeaux, Hop Haut Leveque, Bordeaux, France

[9] Univ Versailles St Quentin Yvelines, Serv Hematol & Oncol, Hop Versailles, Le Chesnay, France

[10] Univ Klinikum TU Dresden, Dresden, Germany

[11] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[12] Univ Chicago, Chicago, IL 60637 USA

[13] Astellas Pharma US Inc, Northbrook, IL USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS7072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7072

引用

页数：4